Cardiol Therapeutics Inc. (CRDL)

NASDAQ: CRDL · IEX Real-Time Price · USD

2.090

+0.090 (4.50%)

At close: Jul 19, 2024, 4:00 PM

2.140

+0.050 (2.39%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Cardiol Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	0	0.08	0	0
Gross Profit	0	0	0	0.08	0	0
Selling, General & Admin	16.99	15.56	22.37	27.87	10.09	7.18
Research & Development	13.42	14.22	18.96	10.87	10.6	3.53
Other Operating Expenses	0	0	0	0	0	3.42
Operating Expenses	30.4	29.79	41.34	38.74	20.69	14.13
Operating Income	-30.4	-29.79	-41.34	-38.66	-20.69	-14.13
Other Expense / Income	-0.19	-1.66	-10.41	-7.03	-0.05	-0.44
Pretax Income	-30.22	-28.13	-30.93	-31.64	-20.64	-13.68
Net Income	-30.22	-28.13	-30.93	-31.64	-20.64	-13.68
Shares Outstanding (Basic)	67	64	63	43	30	26
Shares Outstanding (Diluted)	67	64	63	43	30	26
Shares Change	4.94%	3.13%	44.61%	44.77%	15.63%	-
EPS (Basic)	-0.47	-0.44	-0.49	-0.73	-0.69	-0.53
EPS (Diluted)	-0.47	-0.44	-0.49	-0.73	-0.69	-0.53
Free Cash Flow	-22.18	-25.24	-27.3	-23.55	-9.17	-11.8
Free Cash Flow Per Share	-0.33	-0.39	-0.44	-0.55	-0.31	-0.46
Gross Margin	-	-	-	100.00%	-	-
Operating Margin	-	-	-	-49091.93%	-	-
Profit Margin	-	-	-	-40170.45%	-	-
Free Cash Flow Margin	-	-	-	-29904.22%	-	-
EBITDA	-29.97	-27.88	-30.71	-31.42	-20.41	-13.53
EBITDA Margin	-	-	-	-39890.58%	-	-
Depreciation & Amortization	0.25	0.25	0.22	0.22	0.23	0.15
EBIT	-30.22	-28.13	-30.93	-31.64	-20.64	-13.68
EBIT Margin	-	-	-	-40170.45%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).